Sonam Kumari
National Institutes of Health
CancerCellChemistryApoptosisIn vitroIn vivoChemotherapyProtein kinase D1Glucose uptakePancaMetastasisProstate cancerPancreatic cancerGemcitabineCell cycleCancer researchCancer stem cellCarcinogenesisCell growthMedicineProtein kinase BBiologyCell biologyCancer cell
35Publications
8H-index
260Citations
Publications 34
Newest
#1Sonam Kumari (NIH: National Institutes of Health)H-Index: 8
#2Ruth Adewale (NIH: National Institutes of Health)H-Index: 1
Last. Joanna Klubo-Gwiezdzinska (NIH: National Institutes of Health)H-Index: 16
view all 5 authors...
Source
#1Sonam KumariH-Index: 8
#2Sheema Khan (The University of Texas Rio Grande Valley)
Last. Meena Jaggi (The University of Texas Rio Grande Valley)H-Index: 1
view all 6 authors...
Background Pancreatic cancer is one of the deadliest malignancies, and fourth leading cause of cancer-related deaths in the United States. Aberrant glucose metabolism in cancer cells leads to enhanced tumor growth and aggressiveness. Herein, we have identified an important constituent, steviol from the plant Stevia rebaudiana, which inhibits pancreatic cancer cells via modulation of glucose metabolism and protein translation. Methods Glucose and Lactate assays were performed in pancreatic cancer...
Source
#1Sonam Kumari (NIH: National Institutes of Health)H-Index: 8
#1Sonam Kumari (NIH: National Institutes of Health)
Last. Joanna Klubo-Gwiezdzinska (NIH: National Institutes of Health)H-Index: 16
view all 3 authors...
Hurthle cell thyroid carcinoma (HTC) accounts for 3–5% of all thyroid malignancies. Widely invasive HTC is characterized by poor prognosis and limited responsiveness to standard therapy with radioiodine. The molecular landscape of HTC is significantly different from the genetic signature seen in other forms of thyroid cancer. We performed a comprehensive literature review on the association between the molecular features of HTC and cancer metabolism. We searched the Pubmed, Embase, and Medline d...
1 CitationsSource
#1Sonam Kumari (UTHSC: University of Tennessee Health Science Center)H-Index: 8
#2Sheema Khan (University of Texas at Austin)H-Index: 1
Last. Meena Jaggi (University of Texas at Austin)H-Index: 36
view all 8 authors...
Protein kinase D1 (PKD1) is a serine–threonine kinase that regulates various functions within the cell. Herein, we report the significance of PKD1 expression in glucose metabolism resulting in pancreatic cancer (PanCa) progression and chemo-resistance. PKD1 expression in PanCa was investigated by using immunohistochemistry. Functional and metabolic assays were utilised to analyse the effect of PKD1 expression/knockdown on associated cellular/molecular changes. PKD1 expression was detected in hum...
4 CitationsSource
#1Mohammed Sikander (UTHSC: University of Tennessee Health Science Center)H-Index: 7
#2Shabnam Malik (UTHSC: University of Tennessee Health Science Center)H-Index: 8
Last. Subhash C. ChauhanH-Index: 49
view all 11 authors...
Pancreatic cancer (PanCa) is one of the leading causes of death from cancer in the United States. The current standard treatment for pancreatic cancer is gemcitabine, but its success is poor due to the emergence of drug resistance. Natural products have been widely investigated as potential candidates in cancer therapies, and cucurbitacin D (Cuc D) has shown excellent anticancer properties in various models. However, there is no report on the therapeutic effect of Cuc D in PanCa. In the present ...
7 CitationsSource
#1Kamalika Samanta (UTHSC: University of Tennessee Health Science Center)H-Index: 2
#2Saini Setua (UTHSC: University of Tennessee Health Science Center)H-Index: 7
Last. Subhash C. Chauhan (University of Texas at Austin)H-Index: 49
view all 6 authors...
Pancreatic cancer is one of the deadliest causes of cancer-related death in the United States, with a 5-year overall survival rate of 6 to 8%. These statistics suggest that immediate medical attention is needed. Gemcitabine (GEM) is the gold standard first-line single chemotherapy agent for pancreatic cancer but, after a few months, cells develop chemoresistance. Multiple clinical and experimental investigations have demonstrated that a combination or co-administration of other drugs as chemothe...
21 CitationsSource
#1Prashanth K.B. Nagesh (University of Texas at Austin)H-Index: 10
#2Pallabita Chowdhury (UTHSC: University of Tennessee Health Science Center)H-Index: 12
Last. Murali M. Yallapu (University of Texas at Austin)H-Index: 34
view all 11 authors...
Cellular senescence is one of the prevailing issues in cancer therapeutics that promotes cancer relapse, chemoresistance, and recurrence. Patients undergoing persistent chemotherapy often develop drug-induced senescence. Docetaxel, an FDA-approved treatment for prostate cancer, is known to induce cellular senescence which often limits the overall survival of patients. Strategic therapies that counter the cellular and drug-induced senescence are an unmet clinical need. Towards this an effort was ...
9 CitationsSource
#1Andrew E. Massey (UT: University of Tennessee)H-Index: 5
#2Mohammed Sikander (UT: University of Tennessee)H-Index: 7
Last. Subhash C. Chauhan (UT: University of Tennessee)H-Index: 49
view all 13 authors...
Abstract Pancreatic cancer (PanCa) is a major cause of cancer-related death due to limited therapeutic options. As pancreatic tumors are highly desmoplastic, they prevent appropriate uptake of therapeutic payloads. Thus, our objective is to develop a next-generation nanoparticle system for treating PanCa. We generated a multi-layered Pluronic F127 and polyvinyl alcohol stabilized and poly-L-lysine coated paclitaxel loaded poly(lactic-co-glycolic acid) nanoparticle formulation (PPNPs). This formu...
5 CitationsSource
#1Sheema Khan (UTHSC: University of Tennessee Health Science Center)H-Index: 23
#2Saini Setua (UTHSC: University of Tennessee Health Science Center)H-Index: 7
Last. Subhash C. Chauhan (UTHSC: University of Tennessee Health Science Center)H-Index: 49
view all 14 authors...
Abstract Pancreatic cancer is a complex disease accounting for fibrotic tumors and an aggressive phenotype. Gemcitabine (GEM) is used as a standard therapy, which develops chemoresistance leading to poor patient outcome. We have recently developed a superparamagnetic iron oxide nanoparticle (SPION) formulation of curcumin (SP-CUR), which is a nontoxic, bioactive anti-inflammatory/anti-cancer agent for its enhanced delivery in tumors. In this study, we demonstrate that SP-CUR effectively delivers...
30 CitationsSource
#1Saini SetuaH-Index: 7
#2Sheema KhanH-Index: 23
Last. Subhash C. ChauhanH-Index: 49
view all 8 authors...
Source